Welcome to our dedicated page for Icecure Medical Ltd. SEC filings (Ticker: ICCM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
IceCure Medical Ltd. filings document the company’s status as a foreign private issuer and its disclosures around ProSense cryoablation technology, clinical and regulatory updates, commercial activity, governance and capital structure. Form 6-K reports furnish press releases on financial and operating results, FDA-related matters, medical-conference updates and clinical data for ProSense in tumor-destruction applications.
The filing record also includes proxy materials for shareholder voting, registration-statement references on Forms F-3 and S-8, ordinary-share voting information, executive and board changes, employment and indemnification arrangements, and litigation disclosure related to a prior private placement. These filings frame ICCM’s formal reporting around its medical-device business and public-company obligations.
IceCure Medical reports new clinical data on its ProSense® cryoablation system for kidney, breast, and benign breast tumors, presented at the ECIO 2026 conference. In the ICESECRET kidney cancer trial, cryoablation achieved an 89.4% recurrence-free rate in patients with tumors ≤3 cm, with 83.9% of patients recurrence-free at a median follow-up of 4.0 years.
Independent studies showed no residual cancer at 6 and 12 months in early-stage breast cancer patients and 100% excellent cosmetic outcomes, as well as a 92.9% reduction in fibroadenoma volume at 12 months. ProSense® is described as the first and only device with FDA marketing authorization for local treatment of low-risk breast cancer in women aged 70 and above with adjuvant endocrine therapy.
IceCure Medical Ltd.’s Chief Financial Officer, Peleg Meir, filed an initial ownership report showing 400,000 restricted share units (RSUs) granted on May 17, 2026. Twenty-five percent vest on May 17, 2027, with the remaining 75% vesting in equal quarterly 6.25% installments, all unvested as of the grant date.
IceCure Medical reports that Nasdaq has granted the Company an additional 180-day period, until November 9, 2026, to regain compliance with the exchange’s $1.00 minimum bid price requirement for its ordinary shares.
The extension follows a prior 180-day window that ended on May 11, 2026, during which IceCure did not regain compliance. The Company has indicated it intends to cure the deficiency and may, if needed, implement a reverse share split. If the closing bid price is at least $1.00 for a minimum of 10 consecutive business days before November 9, 2026, Nasdaq will deem the Company compliant, though Nasdaq can require up to 20 days.
The notice has no immediate effect on the listing or trading of IceCure’s ordinary shares, which continue to trade on the Nasdaq Capital Market under the ticker ICCM.
IceCure Medical Ltd. is offering up to $4,339,697 of Ordinary Shares in an at‑the‑market offering under a Sales Agreement with A.G.P./Alliance Global Partners dated May 12, 2026. Sales may occur from time to time on Nasdaq or by other lawful methods. A.G.P. will act as sales agent or principal for sales and will receive a fixed commission of 3.0% of gross sales; there is no escrow arrangement. The company reported 81,237,799 Ordinary Shares outstanding as of May 8, 2026. The prospectus supplement notes a March 2026 registered direct offering that sold 8,000,000 Ordinary Shares at $0.50 per share and generated gross proceeds of approximately $4.0 million, together with Series B and Series C warrants exercisable at $0.55. The net proceeds from this ATM program are intended for working capital and general corporate purposes.
IceCure Medical Ltd. entered into a Sales Agreement with A.G.P./Alliance Global Partners that allows the company to sell ordinary shares from time to time in an at-the-market offering under its existing Form F-3 shelf registration. The company is not required to sell any shares and will direct the timing, price and size of any sales.
A.G.P. will act as sales agent and use commercially reasonable efforts to place shares, earning a 3.0% commission on aggregate gross proceeds from each sale. IceCure plans to use any net proceeds for working capital and general corporate purposes. The agreement includes customary conditions, indemnification, expense reimbursement and a supporting legal opinion on the validity of the shares.
IceCure Medical reported first quarter 2026 results showing continued revenue growth but ongoing losses as it invests in commercialization. Revenue for the three months ended March 31, 2026 rose to $911,000 from $725,000 a year earlier, driven by higher ProSense® sales in the U.S., Canada and Mexico.
Gross profit increased to $295,000 with gross margin improving to 32% from 30%. Operating expenses grew to $4.5 million, mainly from higher research and development and general and administrative costs, while sales and marketing expenses declined. Net loss widened to $4.3 million, or $0.06 per share, similar on a per-share basis to the prior year.
Cash and cash equivalents were $8.1 million as of March 31, 2026, down from $8.9 million as of December 31, 2025, after funding operating activities and capital spending, partially offset by proceeds from share and warrant issuance.
IceCure Medical Ltd. held a Special General Meeting of Shareholders on May 11, 2026. The meeting was initially adjourned at 5:00 p.m. Israel time because there was no quorum, but it reconvened at 6:30 p.m., when a quorum was present.
At the adjourned meeting, shareholders voted on and approved the single agenda item described in the company’s proxy statement filed on April 22, 2026. This report is incorporated by reference into IceCure’s existing registration statements on Form F-3 and Form S-8.